Sutro Biopharma Inc (STRO) Stock Price, Quote & News

Company Profile

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneu...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 881 6500

Fax: 650 553 9659

Website: www.sutrobio.com

Address:

111 Oyster Point Boulevard, South San Francisco, United States

tg4e77 Oct. 28 at 2:28 AM

One of these headed to $5 $GPUS $TLRY $EQ $CGC $STRO 🤔🤔💨💨💣🧨

0 · Reply

slickstoc Oct. 28 at 12:18 AM

0 · Reply

slickstoc Oct. 28 at 12:17 AM

$STRO

0 · Reply

killer_7 Oct. 27 at 3:19 PM

$STRO 👌

0 · Reply

HoHoHoHum Oct. 27 at 3:18 PM

$STRO need 4 more days including today above 1

0 · Reply

dantes13 Oct. 27 at 2:12 PM

$STRO can't go under 1$,if its shit

0 · Reply

killer_7 Oct. 26 at 3:18 AM

$STRO 🤪

0 · Reply

KY3000 Oct. 24 at 6:40 PM

$STRO I think it closes above 1$ is bullish, they won’t have to raise till 2027, that gets them to Astellas milestones and vaxcyte milestones.

0 · Reply

HoHoHoHum Oct. 24 at 9:03 AM

$STRO flirting with that critical 1 level again..

0 · Reply

killer_7 Oct. 24 at 6:09 AM

$STRO

0 · Reply

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

Aug 7, 2025, 4:30 PM EDT - 2 months ago

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:31 PM EDT - 6 months ago

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 1, 2025, 4:05 PM EDT - 6 months ago

Sutro Biopharma to Participate in Upcoming Investor Conferences

Apr 28, 2025, 4:05 PM EDT - 6 months ago

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Mar 15, 2025, 6:40 PM EDT - 8 months ago

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Mar 14, 2025, 12:09 PM EDT - 8 months ago

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

Mar 13, 2025, 4:07 PM EDT - 8 months ago

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Mar 13, 2025, 4:05 PM EDT - 8 months ago

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Mar 3, 2025, 4:05 PM EST - 8 months ago

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Jan 7, 2025, 4:05 PM EST - 10 months ago

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 6:28 PM EST - 10 months ago

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Nov 13, 2024, 4:30 PM EST - 1 year ago

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 4, 2024, 4:05 PM EST - 1 year ago

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sep 23, 2024, 12:46 PM EDT - 1 year ago

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sep 20, 2024, 4:01 PM EDT - 1 year ago

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 14, 2024, 3:00 AM EDT - 1 year ago

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Aug 22, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Aug 13, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Jun 3, 2024, 10:00 AM EDT - 1 year ago

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

May 13, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

Apr 5, 2024, 6:31 PM EDT - 1 year ago

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors

Apr 2, 2024, 6:18 AM EDT - 1 year ago

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Apr 2, 2024, 1:00 AM EDT - 1 year ago

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Mar 25, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Jan 4, 2024, 4:05 PM EST - 1 year ago

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Dec 29, 2023, 4:11 PM EST - 1 year ago

Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement

Dec 14, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

$Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023$